

Pharmacy BULLETIN BOARD

Retail Issue ■ Monday March 9, 2015

Odan Laboratories is pleased to announce the launch of a brand new product:

ODAN POLYSACCHARIDE Iron Complex 150

| Format | McKesson | K&F | PJC | Procurity | VDM | Nu-Quest |
|--------------|----------|--------|--------|-----------|--------|------------|
| 30 capsules | 076403 | 151386 | 758792 | 211842 | 913525 | POLY112ODA |
| 100 capsules | 076404 | 151371 | 758794 | 215503 | 913657 | POLY113ODA |

Odan Polysaccharide Iron Complex 150[®], containing 150 mg of elemental iron, is indicated for the treatment of iron deficiency anemia.

EQUIVALENT TO FERAMAX 150[†]

To order, please contact your wholesaler or contact Odan directly by phone at 1-800-387-9342 or by e-mail at info@odanlab.com.



[†]Odan Polysaccharide Iron Complex 150 is a trademark of Odan Laboratories Ltd.
[†]FeralMax is a registered trademark of BioSynt Inc.

FROM THE NEWSWIRE

MONTREAL: A combination of two once-daily medications for chronic hepatitis C infection has been shown in newly released study results to cure almost all the patients who participated, despite the patients also being co-infected with human immunodeficiency virus (HIV). This patient population historically has been challenging to treat for hepatitis C, in large part due to potential drug-drug interactions between the antiviral therapy regimens used to treat each infection.

Toronto: March is Pharmacist Awareness Month, and the Ontario Pharmacists Association (OPA) is calling on all Ontarians to get to know their local pharmacist and learn how they can become their partner in health. The recently launched website PharmacistsOfferMore.ca highlights the many ways that pharmacists can help patients stay healthy, including many that Ontarians may not be aware of. In addition to using the website as a tool for information on services available, Ontarians are invited to participate in Pharmacist Awareness Month by joining the #PharmacistsKnow conversation on Facebook and Twitter.



Lower Cost Generic Alternative to Andriol^{®1}

◆ **Taro-Testosterone**

Testosterone Undecanoate Capsules 40 mg

- Bioequivalent and Interchangeable with Andriol^{®1}
- High Quality, Lower Price Alternative
- Androgen; testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone²

DIN: 02421186

| Size | UPC | Wholesaler | | | |
|------|--------------|------------|--------|-----------|----------|
| | | McKesson | K&F | Procurity | McMahon |
| 60 | 063691075252 | 071138 | 149748 | 010324 | 10074980 |
| 120 | 063691073333 | 071136 | 149837 | 009946 | 10075001 |

For further information, or to place an order for ◆ **Taro-Testosterone**, please contact your Taro Representative, your wholesaler, our Customer Service department at 1-800-268-1975, or visit our Website at www.taro.ca.

¹Data on file, Taro Pharmaceuticals Inc.

²◆ Taro-Testosterone Product Monograph.

◆ Registered Trademark of N.V. Organon. Used under license.

TARO is a registered trademark of Taro Pharmaceuticals Inc.

SUNNYVALE, Calif.: Accuray Incorporated has announced that the first patient treatment has been completed using the CyberKnife[®] M6[™] System with the InCise[™] Multileaf Collimator (MLC). The treatment was administered as a multidisciplinary effort between Dr. Steven Burton from the Department of Radiation Oncology and Dr. Johnathan Engh from the Department of Neurosurgery at UPMC in Pittsburgh, Pennsylvania. UPMC was one of the InCise MLC evaluation sites working in collaboration with Accuray.

DORVAL, QC: Novartis has announced that Health Canada has approved Cosentyx[™] (secukinumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Offering a new treatment option for Canadians living with plaque psoriasis, Cosentyx[™] is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A.